Einloggen
E-Mail
Passwort
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
News: Aktuelle News
Aktuelle NewsUnternehmenMärkteWirtschaft & ForexRohstoffeZinssätzeBusiness LeadersInstitutionelle AnlegerTermineSektoren

EQS-News: PolyPeptide Group lanciert Börsengang -3-

21.04.2021 | 07:02

group of investors to invest in, or purchase, or take any other action whatsoever with respect to the offered Securities. Each distributor is responsible for undertaking its own relevant target market assessment in respect of the offered Securities and determining appropriate distribution channels.

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of PolyPeptide Group and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. PolyPeptide Group assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.

Except as required by applicable law, PolyPeptide Group has no intention or obligation to update, keep updated or revise this publication or any parts thereof following the date hereof.

None of the underwriters (as defined below) or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. Accordingly, each of the underwriters and the other foregoing persons disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of this announcement and/or any such statement.

Each of Credit Suisse AG, Morgan Stanley Europe SE, Merrill Lynch International, Danske Bank A/S, Joh. Berenberg, Gossler & Co. KG and Zürcher Kantonalbank (the "underwriters") is acting exclusively for PolyPeptide Group and no one else in connection with any transaction referred to in this document. Each of the underwriters will not regard any other person as a client and will not be responsible to anyone other than PolyPeptide Group for providing the protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or arrangement referred to herein.

This publication includes industry and market information based on the PolyPeptide Group's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports prepared by consulting firms (which has been produced based on publications comprising industry data, forecasts, market and customer surveys, analyst reports, other consultant strategy reports and other information made available to it by third party data providers, industry associations, competitors, published accounts, interviews with key market participants/primary interviews and virtual field visits it conducted with industry experts and participants, secondary market research and internal financial and operational information supplied by, or on behalf of, the Group). Readers should be aware that market data and statistics are inherently predictive and speculative and are not necessarily reflective of actual or future market conditions. Such statistics are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the respondents. In addition, the value of comparisons of statistics of different markets is limited by many factors, including that (i) the underlying information is gathered by different methods with varying levels of access and information available in different markets and (ii) different assumptions are applied in compiling the data. Market studies are frequently based on information and assumptions that may not be exact or appropriate and their methodology is by nature forward-looking and speculative.

^[1] Das bereinigte EBITDA wird berechnet als die Summe von (a) Jahresergebnis plus (b) in dem Masse, wie es bei der Ermittlung des Jahresergebnisses abgezogen wird, die Summe von (i) Finanzerträgen und -aufwendungen, (ii) Ertragssteueraufwand, einschliesslich, aber nicht beschränkt auf, bezahlte oder aufgelaufene Steuern, die auf dem Ertrag, Gewinn oder Kapital beruhen (einschliesslich staatlicher, Franchise- und ähnlicher Steuern sowie ausländischer Quellensteuern), und nicht zahlungswirksamer Steuergutschriften, (iii) Abschreibungen und Wertberichtigungen sowie (iv) einmaligen Aufwendungen und Kosten und damit verbundenen Vergünstigungen. Für das Jahr bis zum 31. Dezember 2020 schliesst das bereinigte EBITDA folgende einmalige Posten aus: (i) IPO-Transaktionskosten (EUR 0.52 Millionen) und (ii) Auflösung einer Rückstellung für 2019 (EUR (0.49) Millionen). ^[2] Die bereinigte EBITDA-Marge wird als bereinigtes EBITDA in Prozent des Periodenertrags berechnet. ^[3] Unter der Annahme eines Angebotspreises am mittleren Punkt der Angebotspreisspanne und eines Bruttoerlöses von CHF 200 Millionen für PolyPeptide. -----------------------------------------------------------------------------------------------------------------------

Ende der Medienmitteilungen -----------------------------------------------------------------------------------------------------------------------

Sprache:      Deutsch 
Unternehmen:  PolyPeptide Group 
              Dammstrasse 19 
              CH-6300 Zug 
              Schweiz 
Telefon:      +41 41 723 23 23 
E-Mail:       mediateam@polypeptide.com 
Internet:     www.polypeptide.com 
EQS News ID:  1186904 
 
Ende der Mitteilung EQS Group News-Service 
=------------ 

1186904 2021-04-21

 
Bildlink: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1186904&application_name=news 
 

(END) Dow Jones Newswires

April 21, 2021 01:01 ET (05:01 GMT)

Im Artikel erwähnte Wertpapiere
%Kurs01.01.
CREDIT SUISSE GROUP AG 0.00%9.36 verzögerte Kurse.-17.89%
DANSKE BANK A/S 0.64%110.35 verzögerte Kurse.9.64%
DJ INDUSTRIAL -0.92%34792.67 verzögerte Kurse.13.83%
MORGAN STANLEY -0.32%96.29 verzögerte Kurse.40.96%
Aktuelle Nachrichten "Unternehmen"
09:00DGAP-AFR : home24 SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
DJ
08:59Barclays hebt Ziel für Voestalpine auf 41 Euro - 'Equal Weight'
DP
08:58Lufthansa erholt sich nur langsam vom Corona-Schock
DP
08:56VERGLEICH / Beiersdorf - 1H Eckdaten, Prognosen & Ausblick
DJ
08:56DGAP-NEWS : Bloxxon AG mit neuer Doppelspitze - Daniel Wernicke neuer Co-CEO
DJ
08:55Continental wird dank Reifensparte etwas zuversichtlicher
DP
08:52Deutsche Industrie mit größtem Auftragsplus seit zehn Monaten
RE
08:51VERGLEICH / Continental - 2Q 2021 Eckdaten, Prognosen & Ausblick
DJ
08:48AKTIEN ASIEN/PAZIFIK : Schaukelbörse geht weiter - Plus in Japan, Minus in China
AW
08:46Beiersdorf wächst schneller als erwartet und wird profitabler
DJ
Aktuelle Nachrichten "Unternehmen"